Novartis Stock Falls 12% on Its Third Trial Setback In a Week

Live updates

1. 6d ago

   Novartis Plummets Following Third Drug Trial Setback

   Novartis shares tumbled between 10% and 12% following three consecutive clinical trial setbacks within a single week. The sharp decline marks one of the worst trading days for the pharmaceutical major in over twenty years. The losses accelerated after a critical Phase 3 study for a neuromuscular and dystrophy drug failed to meet expectations. This RNA treatment served as the centerpiece of a $12 billion Avidity buyout. Sympathy drops also hit other sector stocks including DYN and SRPT as investors reassessed the stability of the drug pipeline.

   Why it matters

   The string of consecutive pipeline failures places intense pressure on company leadership and casts doubt on the return expected from a major corporate acquisition. The rapid succession of negative readouts severely damages market confidence in upcoming drug approvals. Biotechnology equities across the wider sector experienced sympathetic pullbacks following the news.

   What is confirmed

   • Novartis stock fell between 10% and 12% following three drug trial setbacks in a week.
   • The centerpiece of a $12 billion Avidity buyout flunked a crucial Phase 3 test.
   • DYN and SRPT slipped in sympathy with the market decline.

   What to watch next

   • Further corporate strategy updates from Novartis leadership regarding the Avidity acquisition.
   • Market recovery or continued decline in shares of DYN and SRPT.
   Sources used for this update (10)

   1. CNBC — Pharma major Novartis plummets 10%, heading for worst day on record after three drug trial setbacks
   2. Reuters — Novartis shares sink on second pipeline setback this week
   3. Fierce Biotech — Novartis’ centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
   4. Yahoo Finance — Novartis Stock Falls 12% on Its Third Trial Setback In a Week
   5. Bloomberg.com — Novartis Sees Avidity Drug Fail in Third Setback in a Week
   6. Barron's — Novartis Stock Tanks Following Third Major Pipeline Setback
   7. Yahoo Finance — NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy
   8. STAT — Neuromuscular drug from Novartis fails in key study, adding to pressure on company
   9. BioSpace — Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
   10. BioPharma Dive — Novartis RNA drug falls short in rare muscle disease study
   confidence 100%